U.S. Markets closed

Tabula Rasa HealthCare’s SinfoníaRx Publishes Comprehensive 2019 Medication Therapy Management Program Performance Report

Year-Over-Year Proficiencies and Growth Documented in Comprehensive Annual Report

MOORESTOWN, N.J., March 19, 2019 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (“TRHC”) (TRHC), a healthcare technology company advancing the field of medication safety, today announced subsidiary company SinfoníaRx has published its 2019 Program Performance Report providing a comprehensive analysis of impressive service efficiencies and program outcomes reported by clients from the preceding 2018 calendar-year.

The annual report presents SinfoníaRx’s depth of clinical intelligence provisioned by the company’s suite of full-service Medication Therapy Management (MTM) solutions, driven by RxCompanion™, SinfoníaRx’s proprietary health information technology platform, and scaled through novel relationships with industry’s leading academic institutions such as The University of Arizona, The Ohio State University, and The University of Texas at Austin Colleges of Pharmacy.

“Each year we are thrilled to present our annual Program Performance Report which highlights SinfoníaRx’s unparalleled ability to deliver best-in-class MTM services to millions of Americans nationwide,” said SinfoníaRx CEO, Sandra Leal, PharmD, MPH, FAPhA. “Aligned with Tabula Rasa HealthCare’s family of diverse technology-driven companies, SinfoníaRx continues to demonstrate year-over-year program proficiency and growth, further instilling SinfoníaRx as a premier provider of the highest quality innovative healthcare solutions for patients, providers, health plans, and community pharmacies.”

“We are especially pleased to announce that SinfoníaRx now offers TRHC’s Medication Risk Management and Optimized Opioid Solution™ services to enhance its offerings and expects to drive outcomes and savings even further for our clients,” added TRHC Chairman and CEO, Calvin H. Knowlton, PhD.

Highlights featured in the 2018 annual report include an increase to 4.68 million interventions completed in 2018, compared to 3.3 million in 2017. SinfoníaRx also delivered more than 459,000 Comprehensive Medication Reviews in 2018 vs. a documented 307,000 in 2017. The complete 2019 SinfoníaRx Program Performance Report can be found on the company’s website by clicking here.

The publication of the 2019 SinfoníaRx Program Performance Report comes as the company announces representation at The Academy of Managed Care Pharmacy (AMCP) 2019 Annual Meeting, hosted March 25-28 in San Diego, California. SinfoníaRx will exhibit novel solutions, powered by RxCompanion, which provide robust analytics and enhanced patient engagement opportunities for pharmacists in the community. Conference attendees may visit SinfoníaRx at exhibit booth #239.

To view the 2019 SinfoníaRx Program Performance Report, and to learn more about SinfoníaRx’s suite of comprehensive MTM services, visit sinfoniarx.com. For more information on Tabula Rasa HealthCare and the company’s proprietary medication risk management solution set, visit tabularashealthcare.com.

About Tabula Rasa HealthCare
TRHC (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs, and manage risk. TRHC provides solutions for a range of payers, providers and other healthcare organizations. For more information, visit TRHC.com.

About SinfoníaRx
SinfoníaRx, a Tabula Rasa HealthCare company, is a leading provider of Medication Therapy Management (MTM) services. Through a comprehensive suite of innovative healthcare solutions, SinfoníaRx provides direct support to health plans, health systems, provider organizations, and pharmacies. SinfoníaRx’s staff of nationally renowned clinical pharmacists and interprofessional team work directly with caregivers, patients, and providers to ensure the most effective and safest medication therapy possible. For more information, visit sinfoniarx.com.

Forward-Looking Statements
This press release includes forward-looking statements that we believe to be reasonable as of today’s date. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 14, 2018, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website http://ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.

Media Contact                                                Investors
Dianne Semingson                                          Bob East or Asher Dewhurst
dsemingson@trhc.com                                   Westwicke Partners
T: 215-0870-0829                                            tabularasa@westwicke.com
                                                                        T: 433-213-0500